Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Cefiderocol is an injectable siderophore cephalosporin discovered and being developed by Shionogi & Co., Ltd., Japan. As with other β-lactam antibiotics, the principal antibacterial/bactericidal activity of cefiderocol occurs by inhibition of Gram-negative bacterial cell wall synthesis by binding to penicillin binding proteins; however, it is unique in that it enters the bacterial periplasmic space as a result of its siderophore-like property and has enhanced stability to β-lactamases. The chemical structure of cefiderocol is similar to both ceftazidime and cefepime, which are third- and fourth-generation cephalosporins, respectively, but with high stability to a variety of β-lactamases, including AmpC and extended-spectrum β-lactamases (ESBLs). Cefiderocol has a pyrrolidinium group in the side chain at position 3 like cefepime and a carboxypropanoxyimino group in the side chain at position 7 of the cephem nucleus like ceftazidime. The major difference in the chemical structures of cefiderocol, ceftazidime and cefepime is the presence of a catechol group on the side chain at position 3. Together with the high stability to β-lactamases, including ESBLs, AmpC and carbapenemases, the microbiological activity of cefiderocol against aerobic Gram-negative bacilli is equal to or superior to that of ceftazidime-avibactam and meropenem, and it is active against a variety of Ambler class A, B, C and D β-lactamases. Cefiderocol is also more potent than both ceftazidime-avibactam and meropenem versus Acinetobacter baumannii, including meropenem non-susceptible and multidrug-resistant (MDR) isolates. Cefiderocol's activity against meropenem-non-susceptible and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriales is comparable or superior to ceftazidime-avibactam. Cefiderocol is also more potent than both ceftazidime-avibactam and meropenem against all resistance phenotypes of Pseudomonas aeruginosa and against Stenotrophomonas maltophilia. The current dosing regimen being used in phase III studies is 2 g administered intravenously every 8 h (q8 h) using a 3-h infusion. The pharmacokinetics of cefiderocol are best described by a three-compartment linear model. The mean plasma half-life (t ½) was ~ 2.3 h, protein binding is 58%, and total drug clearance ranged from 4.6-6.0 L/h for both single- and multi-dose infusions and was primarily renally excreted unchanged (61-71%). Cefiderocol is primarily renally excreted unchanged and clearance correlates with creatinine clearance. Dosage adjustment is thus required for both augmented renal clearance and in patients with moderate to severe renal impairment. In vitro and in vivo pharmacodynamic studies have reported that as with other cephalosporins the pharmacodynamic index that best predicts clinical outcome is the percentage of time that free drug concentrations exceed the minimum inhibitory concentration (%fT > MIC). In vivo efficacy of cefiderocol has been studied in a variety of humanized drug exposure murine and rat models of infection utilizing a variety of MDR and extremely drug resistant strains. Cefiderocol has performed similarly to or has been superior to comparator agents, including ceftazidime and cefepime. A phase II prospective, multicenter, double-blind, randomized clinical trial assessed the safety and efficacy of cefiderocol 2000 mg q8 h versus imipenem/cilastatin 1000 mg q8 h, both administered intravenously for 7-14 days over 1 h, in the treatment of complicated urinary tract infection (cUTI, including pyelonephritis) or acute uncomplicated pyelonephritis in hospitalized adults. A total of 452 patients were initially enrolled in the study, with 303 in the cefiderocol arm and 149 in the imipenem/cilastatin arm. The primary outcome measure was a composite of clinical cure and microbiological eradication at the test-of-cure (TOC) visit, that is, 7 days after the end of treatment in the microbiological intent-to-treat (MITT) population. Secondary outcome measures included microbiological response per pathogen and per patient at early assessment (EA), end of treatment (EOT), TOC, and follow-up (FUP); clinical response per pathogen and per patient at EA, EOT, TOC, and FUP; plasma, urine and concentrations of cefiderocol; and the number of participants with adverse events. The composite of clinical and microbiological response rates was 72.6% (183/252) for cefiderocol and 54.6% (65/119) for imipenem/cilastatin in the MITT population. Clinical response rates per patient at the TOC visit were 89.7% (226/252) for cefiderocol and 87.4% (104/119) for imipenem/cilastatin in the MITT population. Microbiological eradication rates were 73.0% (184/252) for cefiderocol and 56.3% (67/119) for imipenem/cilastatin in the MITT population. Additionally, two phase III clinical trials are currently being conducted by Shionogi & Co., Ltd., Japan. The two trials are evaluating the efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens and evaluating the efficacy of cefiderocol in the treatment of adults with hospital-acquired bacterial pneumonia, ventilator-associated pneumonia or healthcare-associated pneumonia caused by Gram-negative pathogens. Cefiderocol appears to be well tolerated (minor reported adverse effects were gastrointestinal and phlebitis related), with a side effect profile that is comparable to other cephalosporin antimicrobials. Cefiderocol appears to be well positioned to help address the increasing number of infections caused by carbapenem-resistant and MDR Gram-negative bacilli, including ESBL- and carbapenemase-producing strains (including metallo-β-lactamase producers). A distinguishing feature of cefiderocol is its activity against resistant P. aeruginosa, A. baumannii, S. maltophilia and Burkholderia cepacia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Siderophore- mimicking antibiotics have gained traction with the US Food and Drug Administration (FDA) approval of cefiderocol (Fetroja) 179 , which exploits the natural bacterial siderophore uptake systems to increase efficacy of the antibiotic, signifying the feasibility of targeting metal uptake systems in bacteria to use as human therapies.”
From Nutritional immunity: the battle for nutrient metals at the host–pathogen interface (2022) · cites this paper as [179]
Citations
Cites
International Organization for Standardization
(2011) · SpringerReference · doi:10.1007/springerreference_16847 · Cited by 12,534
Performance standards for antimicrobial susceptibility testing
Ferraro, M. J. (2001) · Cited by 9,667
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Carbapenems: Past, Present, and Future
Papp-Wallace, K. M., Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-11 · Cited by 1,502
Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
Gupta, N., Limbago, B. M., Patel, J. B., & Kallen, A. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir202 · Cited by 1,033
The global epidemiology of carbapenemase-producing Enterobacteriaceae
van Duin, D., & Doi, Y. (2017) · Virulence · doi:10.1080/21505594.2016.1222343 · Cited by 1,004
Global spread of carbapenem-resistant Acinetobacter baumannii
Higgins, P. G., Dammhayn, C., Hackel, M., & Seifert, H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp428 · Cited by 607
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
Zhanel, G. G., Lawson, C. D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P. R. S., Denisuik, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2013) · Drugs · doi:10.1007/s40265-013-0013-7 · Cited by 433
Self-citationPortsmouth, S., van Veenhuyzen, D., Echols, R., Machida, M., Ferreira, J. C. A., Ariyasu, M., Tenke, P., & Nagata, T. D. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30554-1 · Cited by 420
Research works printed but not linked: 8
- Ito A, Nishikawa T, Matsumoto S, Fukuhara N, Nakamura R, Tsuji M, et al. S-649266, a novel siderophore cephalosporin: II. Impact of active transport via iron regulated outer membrane proteins on resistance selection. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
- Hackel M, Tsuji M, Echols R, Sahm D. In vitro antibacterial activity of cefiderocol (S-649266) against Gram-negative clinical strains collected in North America and Europe (SIDERO-WT-2014 study). In: IDWeek; New Orleans. 2016. · DOI
- Tsuji M, Hackel M, Echols R, Yamano Y, Sahm DF. In vitro activity of cefiderocol against globally collected carbapenem-resistant Gram-negative bacteria isolated from urinary tract source: SIDERO-CR-2014/2016. In: IDWeek; San Diego. 2017. · DOI
- Ito A, Kohira N, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y, et al. S-649266, a novel siderophore cephalosporin: I. In vitro activity against Gram-negative bacteria including multidrug-resistant strains. In: 54th Intersci. Conf. Antimicrob. Agents Chemother; Washington, DC. 2014.
- Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. S-649266, a novel siderophore cephalosporin: V. Pharmacodynamic assessment in murine thigh infection models. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
- Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. S-649266, a novel siderophore cephalosporin: VI. Magnitude of PK/PD parameter required for efficacy in murine lung infection model. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
- Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. S-649266, a novel siderophore cephalosporin: VII. Magnitude of PK/PD parameter required for efficacy in murine thigh infection model. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
- Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. S-649266, a novel siderophore cephalosporin: IV. In vivo efficacy in various murine infection models. In: 54th Intersci. Conf. Antimicrob. Agents Chemother.; Washington, DC. 2014.
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Nutritional immunity: the battle for nutrient metals at the host–pathogen interface
Murdoch, C. C., & Skaar, E. P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00745-6 · Cited by 701
Terreni, M., Taccani, M., & Pregnolato, M. (2021) · Molecules · doi:10.3390/molecules26092671 · Cited by 596
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Sato, T., & Yamawaki, K. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz826 · Cited by 379
Karampatakis, T., Tsergouli, K., & Behzadi, P. (2023) · Antibiotics · doi:10.3390/antibiotics12020234 · Cited by 339
Metadata
- Authors
- Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., Lagacé-Wiens, P. R. S., Walkty, A. J., Noreddin, A., Lynch III, J. P., & Karlowsky, J. A.
- Affiliations
- Health Sciences Centre (CA)
- University of Manitoba (CA)
- Shared Health (CA)
- University of Sharjah (AE)
- Corresponding author
- Zhanel, George G.
- ORCID
- Venue
- Drugs
- Published
- 2019-02
- Volume
- 79
- Issue
- 3
- Pages
- 271-289
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2912906332
- Cited by
- 446
- References
- 48
- Citations by year
- 2026: 49 · 2025: 66 · 2024: 58 · 2023: 61 · 2022: 68 · 2021: 60 · 2020: 59 · 2019: 25
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- cefiderocol, siderophore cephalosporin, carbapenem resistance, multidrug resistance, Gram-negative bacilli, beta-lactamase stability, penicillin-binding proteins, Acinetobacter baumannii, KPC, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, ceftazidime-avibactam, meropenem
- MeSH terms
- Meropenem, Cefiderocol, Animals, Anti-Bacterial Agents, Ceftazidime, Cephalosporins, Clinical Trials as Topic, Dose-Response Relationship, Drug, Drug Combinations, Gram-Negative Bacteria, Humans, Molecular Structure, Carbapenems, Randomized Controlled Trials as Topic, Gram-Negative Bacterial Infections, Siderophores, Drug Resistance, Multiple, Bacterial, Azabicyclo Compounds, beta-Lactamase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. https://app.cochat.ai/papers/10.1007/s40265-019-1055-2
- The paper
- Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., Lagacé-Wiens, P. R. S., Walkty, A. J., Noreddin, A., Lynch III, J. P., & Karlowsky, J. A. (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs. https://doi.org/10.1007/s40265-019-1055-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.